Llwytho...
Early analysis of surrogate endpoints for metastatic melanoma in immune checkpoint inhibitor trials
Recent major phase III trials led to the approval of immune checkpoint inhibitors (ipilimumab, pembrolizumab, and nivolumab) in metastatic malignant melanoma (MM). We aim to assess whether median progression-free survival, and 1 and 2-year overall survival (OS) rates are reliable surrogate endpoints...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Medicine (Baltimore) |
|---|---|
| Prif Awduron: | , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Wolters Kluwer Health
2016
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4937921/ https://ncbi.nlm.nih.gov/pubmed/27368007 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000003997 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|